Skip to main content

Table 2. Individual parasite reduction ratios (PRR) and half-life (t½) for 800 mg ferroquine

From: A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study

Subject

PRR (95 % CI)

t½, h (95 % CI)

R101

73

(47–115)

7.75

(7.01–8.66)

R102

140

(99–198)

6.73

(6.29–7.24)

R103

375

(222–634)

5.61

(5.16–6.16)

R104

244

(129–460)

6.05

(5.43–6.84)

R105

250

(116–542)

6.02

(5.29–7.00)

R106+

78

(60–101)

7.64

(7.21–8.13)

R107

124

(69–220)

6.91

(6.17–7.85)

R108

479

(356–646)

5.39

(5.14–5.66)

  1. + Subject R106 had low levels of parasitaemia for a period of time after 144 h post treatment. Data for analysis were censored at 144 h
Back to article page